GlassScriptPhysician profile
Kenneth Randell Grossman
NPI 1184684672
$3,108.42
in general payments reported to CMS, 2019-2025
24 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $150 · 2021: $345 · 2022: $492 · 2023: $780 · 2024: $525 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $532.28 | 2022-2025 | |
| Alcon Vision LLC | $337.52 | 2020-2025 | Hydrus Microstent, Clareon, Rocklatan |
| Glaukos Corporation | $305.37 | 2021-2025 | Idosetr, Istent Infinite, Kxl System (Not Refurbished) |
| Alimera Sciences, INC. | $298.03 | 2019-2024 | Iluvien, Yutiq |
| Allergan, INC. | $205.59 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $204.58 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $191.07 | 2023-2025 | Syfovre |
| Vanda Pharmaceuticals INC. | $180.58 | 2022-2023 | Hetlioz |
| Sight Sciences, INC. | $148.45 | 2021-2024 | Omni Surgical System |
| Amgen INC. | $119.38 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $97.39 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $78.67 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Mallinckrodt Hospital Products INC. | $63.95 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $63.29 | 2022 | |
| Genentech USA, INC. | $37.97 | 2022-2023 | Vabysmo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $34.74 | 2022-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $34.73 | 2024-2025 | Xdemvy |
| Rxsight INC | $30.56 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece |
| Biotissue Holdings INC. | $29.74 | 2021 | |
| Sun Pharmaceutical Industries INC. | $29.70 | 2019 | |
| Kala Pharmaceuticals, INC. | $28.88 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $26.95 | 2025 | Yutiq |
| Ivantis, INC | $14.51 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.49 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Grossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.